Daiichi Sankyo Co. Ltd. presented details of promising Phase III results for its developmental cancer drug pexidartinib at the recent American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, that it says will be used to support a planned US NDA in a rare tumor type with no currently approved therapies.
One shadow lingering over the promising data however was hepatic toxicity, although the company does not appear too concerned and...